| Date | Title | | | 01/20/12 | Idera Pharmaceuticals Announces Favorable Data from Phase 1b Study of
IMO-2055 in Combination with Tarceva(R) and
Avastin(R) in Patients with Advanced Non-Small
Cell Lung Cancer| CAMBRIDGE, Mass., Jan 20, 2012 (BUSINESS WIRE) --Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced favorable
safety and efficacy results from a Phase 1b study of IMO-2055, a TLR9
agonist, in combination with Tarceva(R) and Avastin(R)
in thirty-six patients with advanced non-small cell lung cancer (NSCLC)
who have previously failed one or more prior therapies. In this trial,
the combination of IMO-2055 with Tarceva and Avastin was well tolerated.
... |
|  | | 01/09/12 | Idera Pharmaceuticals Announces Selection of Toll-like Receptor Agonist Candidates for Evaluation as Vaccine Adjuvants by Merck| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 9, 2012--
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that Merck,
known as MSD outside the United States and Canada, has selected several
novel Toll-like Receptor (TLR) agonists targeted to TLR7, TLR8 or TLR9
for evaluation and use as vaccine adjuvant candidates under the
companies' collaboration and license agreement.
“We are very pleased to have created multiple novel TLR agonists for
... |
| | | 12/13/11 | Idera Pharmaceuticals Presents Data in Preclinical Models of Lymphoma on IMO-4200, a Dual Agonist of TLRs 7 and 8, at the American Society for Hematology Meeting| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 13, 2011--
Idera Pharmaceuticals (Nasdaq: IDRA) today announced that it presented
new data showing that IMO-4200, a dual agonist of Toll-like receptor
(TLR) 7 and TLR8, in combination with approved cancer treatments
increased antitumor activity in preclinical models of lymphoma. The
presentation by Idera scientists, entitled “IMO-4200, a novel TLR7 and
TLR8 dual agonist, enhances antitumor effect of ofatumumab,... |
| | | 12/01/11 | Idera Pharmaceuticals Announces FDA Authorization to Proceed with a Phase 2 Clinical Trial of IMO-3100 in Patients with Psoriasis| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 1, 2011--
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced the receipt
of verbal notification from the Food and Drug Administration (FDA) that
the company may proceed with a Phase 2 clinical trial of IMO-3100 in
patients with psoriasis based on a trial protocol submitted by the
company in October 2011. IMO-3100 is a dual antagonist of Toll-like
receptor (TLR) 7 and TLR9 and is in clinical development ... |
| |
|
